Why has Merck's Keytruda sales growth slowed from 30% to 15% year-over-year in Q3?

Introduction

Keytruda's sales growth deceleration from 30% to 15% year-over-year in Q3 presents a complex challenge for Merck. This analysis will systematically identify, validate, and address potential root causes while considering both immediate and long-term implications for the product's performance.

I'll approach this issue by first clarifying key details, ruling out external factors, and then diving deep into product understanding, metric breakdown, and data-driven hypothesis generation. We'll then conduct a thorough root cause analysis, propose validation methods, and outline a comprehensive resolution plan.

Step 1

Clarifying Questions (3 minutes)

• Looking at the timing, I'm thinking there might be seasonal factors at play. Has Keytruda historically shown any quarterly sales patterns?

Why it matters: Seasonal trends could explain the slowdown and inform our analysis approach. Expected answer: Some seasonality, but not typically this pronounced. Impact on approach: If seasonal, we'd focus on year-over-year comparisons and cyclical factors.

• Considering market dynamics, has there been any significant change in competitor products or pricing?

Why it matters: Competitive pressures could be driving the slowdown. Expected answer: No major new entrants, but some pricing pressure from existing competitors. Impact on approach: We'd need to analyze market share and pricing strategies more closely.

• Regarding product lifecycle, has Keytruda recently expanded or lost any major indications?

Why it matters: Changes in approved uses could significantly impact sales growth. Expected answer: No major changes in indications, but some new combination therapies approved. Impact on approach: We'd investigate the uptake and impact of these new combination therapies.

• Thinking about internal factors, have there been any changes to Merck's sales or marketing strategies for Keytruda?

Why it matters: Strategic shifts could explain the growth rate change. Expected answer: Some adjustments to marketing focus, but no major overhauls. Impact on approach: We'd examine the effectiveness of recent marketing initiatives.

• Considering data integrity, has there been any change in how sales or growth rates are calculated or reported?

Why it matters: Ensures we're comparing apples to apples in our analysis. Expected answer: No changes in calculation methods or reporting. Impact on approach: Confirms we can focus on actual performance rather than reporting anomalies.